| pubmed-article:15314548 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15314548 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:15314548 | lifeskim:mentions | umls-concept:C0681867 | lld:lifeskim |
| pubmed-article:15314548 | lifeskim:mentions | umls-concept:C0024623 | lld:lifeskim |
| pubmed-article:15314548 | lifeskim:mentions | umls-concept:C1511562 | lld:lifeskim |
| pubmed-article:15314548 | lifeskim:mentions | umls-concept:C0918027 | lld:lifeskim |
| pubmed-article:15314548 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:15314548 | pubmed:dateCreated | 2004-8-17 | lld:pubmed |
| pubmed-article:15314548 | pubmed:abstractText | The effect of adjuvant immunochemotherapy including OK-432 (Picibanil) on survival was assessed in patients who underwent curative resection of gastric cancer. Patients enrolled in this randomized controlled study were randomly assigned to group A or group B. Group A patients received 800 mg/d 5'-DFUR (Furtulon) for 2 years from 2 weeks after the operation. Group B patients received OK-432 plus 5'-DFUR by the same regimen as in group A. This study enrolled 288 patients, and 1 patient with malignant lymphoma was excluded. Among the remaining 287 patients, 143 and 144 were allocated to group A and group B, respectively, and their data were included in statistical analysis. The 5-year survival rates for groups A and B were 62.9% and 63.8%, respectively, showing no significant difference (P = 0.7996). | lld:pubmed |
| pubmed-article:15314548 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15314548 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15314548 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15314548 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15314548 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15314548 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15314548 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15314548 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15314548 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15314548 | pubmed:issn | 1524-9557 | lld:pubmed |
| pubmed-article:15314548 | pubmed:author | pubmed-author:MatsudaMiyuki... | lld:pubmed |
| pubmed-article:15314548 | pubmed:author | pubmed-author:TodoSatoruS | lld:pubmed |
| pubmed-article:15314548 | pubmed:author | pubmed-author:KondoMasaoM | lld:pubmed |
| pubmed-article:15314548 | pubmed:author | pubmed-author:SaitoKazuoK | lld:pubmed |
| pubmed-article:15314548 | pubmed:author | pubmed-author:SatoYujiY | lld:pubmed |
| pubmed-article:15314548 | pubmed:author | pubmed-author:RyomaYoshikiY | lld:pubmed |
| pubmed-article:15314548 | pubmed:author | pubmed-author:OnoKen-IchiK | lld:pubmed |
| pubmed-article:15314548 | pubmed:author | pubmed-author:KohashiShigec... | lld:pubmed |
| pubmed-article:15314548 | pubmed:author | pubmed-author:TakahashiNori... | lld:pubmed |
| pubmed-article:15314548 | pubmed:author | pubmed-author:TakahashiSyus... | lld:pubmed |
| pubmed-article:15314548 | pubmed:author | pubmed-author:SinoharaToshi... | lld:pubmed |
| pubmed-article:15314548 | pubmed:author | pubmed-author:ShirotoHirosh... | lld:pubmed |
| pubmed-article:15314548 | pubmed:author | pubmed-author:KondoYukihumi... | lld:pubmed |
| pubmed-article:15314548 | pubmed:author | pubmed-author:UchinoJun-Ich... | lld:pubmed |
| pubmed-article:15314548 | pubmed:copyrightInfo | Copyright 2004 Lippincott Williams & Wilkins | lld:pubmed |
| pubmed-article:15314548 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15314548 | pubmed:volume | 27 | lld:pubmed |
| pubmed-article:15314548 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15314548 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15314548 | pubmed:pagination | 394-7 | lld:pubmed |
| pubmed-article:15314548 | pubmed:dateRevised | 2008-3-18 | lld:pubmed |
| pubmed-article:15314548 | pubmed:meshHeading | pubmed-meshheading:15314548... | lld:pubmed |
| pubmed-article:15314548 | pubmed:meshHeading | pubmed-meshheading:15314548... | lld:pubmed |
| pubmed-article:15314548 | pubmed:meshHeading | pubmed-meshheading:15314548... | lld:pubmed |
| pubmed-article:15314548 | pubmed:meshHeading | pubmed-meshheading:15314548... | lld:pubmed |
| pubmed-article:15314548 | pubmed:meshHeading | pubmed-meshheading:15314548... | lld:pubmed |
| pubmed-article:15314548 | pubmed:meshHeading | pubmed-meshheading:15314548... | lld:pubmed |
| pubmed-article:15314548 | pubmed:meshHeading | pubmed-meshheading:15314548... | lld:pubmed |
| pubmed-article:15314548 | pubmed:meshHeading | pubmed-meshheading:15314548... | lld:pubmed |
| pubmed-article:15314548 | pubmed:meshHeading | pubmed-meshheading:15314548... | lld:pubmed |
| pubmed-article:15314548 | pubmed:meshHeading | pubmed-meshheading:15314548... | lld:pubmed |
| pubmed-article:15314548 | pubmed:meshHeading | pubmed-meshheading:15314548... | lld:pubmed |
| pubmed-article:15314548 | pubmed:meshHeading | pubmed-meshheading:15314548... | lld:pubmed |
| pubmed-article:15314548 | pubmed:meshHeading | pubmed-meshheading:15314548... | lld:pubmed |
| pubmed-article:15314548 | pubmed:meshHeading | pubmed-meshheading:15314548... | lld:pubmed |
| pubmed-article:15314548 | pubmed:meshHeading | pubmed-meshheading:15314548... | lld:pubmed |
| pubmed-article:15314548 | pubmed:articleTitle | A randomized controlled study of immunochemotherapy with OK-432 after curative surgery for gastric cancer. | lld:pubmed |
| pubmed-article:15314548 | pubmed:affiliation | First Department of Surgery, School of Medicine, Hokkaido University, Sapporo, Japan. yuchan@med.hokudai.ac.jp | lld:pubmed |
| pubmed-article:15314548 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15314548 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:15314548 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
